Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy

被引：11
作者：
Montagnon, Carmen M. [1 ]
Lehman, Julia S. [1 ,2 ]
Murrell, Dedee F. [3 ]
Camilleri, Michael J. [1 ,2 ]
Tolkachjov, Stanislav N. [4 ]
机构：
[1] Mayo Clin, Dept Dermatol, Rochester, MN USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[3] Univ New South Wales, St George Hosp, Dept Dermatol, Sydney, NSW, Australia
[4] Epiphany Dermatol, Dallas, TX 75019 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 84卷 / 06期
关键词：
azathioprine; dapsone; intraepithelial autoimmune bullous dermatoses; IVIG; mycophenolate mofetil; pemphigus erythematosus; pemphigus foliaceus; pemphigus herpetiformis; paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome; Pemphigus Disease Activity Index; pemphigus vulgaris; rituximab; INTRAVENOUS IMMUNOGLOBULIN THERAPY; DISORDER INTENSITY SCORE; SEVERE PARANEOPLASTIC PEMPHIGUS; CYCLOPHOSPHAMIDE PULSE THERAPY; GLUCOCORTICOID-SPARING AGENT; LINKED-IMMUNOSORBENT-ASSAY; MYCOPHENOLATE-MOFETIL; ADJUVANT THERAPY; IMMUNOSUPPRESSIVE AGENTS; PLASMA-EXCHANGE;
D O I：
10.1016/j.jaad.2021.02.073
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Intraepithelial autoimmune blistering dermatoses are a rare group of skin disorders characterized by disruptions of inter-keratinocyte connections within the epidermis through the action of autoantibodies. The second article in this continuing medical education series presents validated disease activity scoring systems, serologic parameters of disease, treatments, and clinical trials for pemphigus and its subtypes.
引用
收藏
页码：1523 / 1537
页数：15
相关论文
共 154 条
  • [1] Abasq C, 2009, ARCH DERMATOL, V145, P529, DOI 10.1001/archdermatol.2009.9
  • [2] Necrotizing fasciitis caused by Cryptococcus neoformans in a patient with pemphigus vegetans
    Adachi, M.
    Tsuruta, D.
    Imanishi, H.
    Ishii, M.
    Kobayashi, H.
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2009, 34 (08) : E751 - E753
  • [3] First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up
    Ahmed, A. Razzaque
    Nguyen, Tegan
    Kaveri, Srini
    Spigelman, Zachary S.
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 34 : 25 - 31
  • [4] Long-Term Remissions in Recalcitrant Pemphigus Vulgaris
    Ahmed, A. Razzaque
    Kaveri, Srini
    Spigelman, Zachary
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) : 2693 - 2694
  • [5] Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin
    Ahmed, A. Razzaque
    Spigelman, Zachary
    Cavacini, Lisa A.
    Posner, Marshall R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (17) : 1772 - 1779
  • [6] Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy
    Ahmed, AR
    Sami, N
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (01) : 42 - 49
  • [7] Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment
    Ahmed, AR
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (05) : 679 - 690
  • [8] AHMED AR, 1984, INT J DERMATOL, V23, P135
  • [9] A randomized double-blind trial of intravenous immunoglobulin for pemphigus
    Amagai, Masayuki
    Ikeda, Shigaku
    Shimizu, Hiroshi
    Iizuka, Hajime
    Hanada, Katsumi
    Aiba, Setsuya
    Kaneko, Fumio
    Izaki, Seiichi
    Tamaki, Kunihiko
    Ikezawa, Zenro
    Takigawa, Masahiro
    Seishima, Mariko
    Tanaka, Toshihiro
    Miyachi, Yoshiki
    Katayama, Ichiro
    Horiguchi, Yuji
    Miyagawa, Sachiko
    Furukawa, Fukumi
    Iwatsuki, Keiji
    Hide, Michihiro
    Tokura, Yoshiki
    Furue, Masutaka
    Hashimoto, Takashi
    Ihn, Hironobu
    Fujiwara, Sakuhei
    Nishikawa, Takeji
    Ogawa, Hideoki
    Kitajima, Yasuo
    Hashimoto, Koji
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (04) : 595 - 603
  • [10] Targeted Therapies for Autoimmune Bullous Diseases: Current Status
    Amber, Kyle T.
    Maglie, Roberto
    Solimani, Farzan
    Eming, Ruediger
    Hertl, Michael
    [J]. DRUGS, 2018, 78 (15) : 1527 - 1548
12345678910